Secosteroid–Isatin Hybrids as Novel Estrogen Receptor α Modulators with Selective Activity Against Hormone-Dependent Breast Cancer
Estrogen receptor α (ERα) remains the principal molecular driver of hormone-dependent breast cancer. In this study, we designed, synthesized, and biologically evaluated a new series of secosteroid–isatin hybrids as potential ERα-targeting anticancer agents. The lead compounds, (Z)-3a and (Z)-3b, inhibited MCF-7 cell growth with IC50 values of 6.8 and 6.0 μM, respectively, comparable to cisplatin; they were approximately threefold less potent against epithelial cells than against the target cell model of ERα-positive breast cancer. Mechanistic studies demonstrated that both compounds induced a concentration-dependent depletion of ERα protein, accompanied by downregulation of the ERα-dependent proliferative mediator cyclin D1 and the anti-apoptotic protein Mcl-1, together with accumulation of cleaved PARP, indicating activation of apoptotic cell death. Importantly, an estrogen response element (ERE)-driven luciferase reporter assay demonstrated potent concentration-dependent suppression of 17β-estradiol-induced ERα transcriptional activity, with nearly complete inhibition achieved at higher concentrations, confirming that these compounds function as effective antagonists of ERα-dependent gene transcription. Furthermore, both lead compounds exhibited predominantly synergistic interactions with doxorubicin and heliomycin, suggesting their potential utility in combination therapy. Collectively, these findings identify secosteroid–isatin hybrids as a previously unexplored class of ERα modulators with efficient suppression of estrogen receptor α signaling and induction of apoptosis, which highlights this scaffold as a promising platform for the development of next-generation therapeutics for hormone-dependent breast cancer.
Authors
- Andrey Sergeevich Dmitrenok (ORCID: https://orcid.org/0000-0003-3736-0459)
- Olga E. Andreeva (ORCID: https://orcid.org/0000-0002-6015-6619)
- Alexander Olegovich Terent'ev (ORCID: https://orcid.org/0000-0001-8018-031X)
- Andrey Egorovich Shchekotikhin (ORCID: https://orcid.org/0000-0002-6595-0811)
- E. I. Chernoburova
- Eugene I. Bozhenko (ORCID: https://orcid.org/0009-0004-5120-1918)
- Fedor B. Bogdanov (ORCID: https://orcid.org/0000-0002-0976-0335)
- Diana I. Salnikova (ORCID: https://orcid.org/0000-0002-0809-3710)
- Alexey I. Ilovaisky (ORCID: https://orcid.org/0000-0003-2204-2191)
- Mikhail Evgenievich Minyaev (ORCID: https://orcid.org/0000-0002-4089-3697)
- Danila Vladimirovich Sorokin (ORCID: https://orcid.org/0000-0002-1264-7405)
- Ivan Andreevich Yaremenko (ORCID: https://orcid.org/0000-0003-1068-9051)
- Valentina M. Merkulova
- Igor V. Zavarzin (ORCID: https://orcid.org/0000-0002-8194-5756)
- Alexander Mikhailovich Scherbakov (ORCID: https://orcid.org/0000-0002-2974-9555)
- Quoc Long Pham (ORCID: https://orcid.org/0000-0001-6964-2341)
- Đỗ Hữu Nghị (ORCID: https://orcid.org/0000-0002-6272-0922)
- Thu Quynh Dang (ORCID: https://orcid.org/0000-0001-6437-6304)
Institutions
- Russian Academy of Sciences (RU)
- Ton Duc Thang University (VN)
- N.D. Zelinsky Institute of Organic Chemistry (RU)
- Russian Cancer Research Center NN Blokhin (RU)
- Gause Institute of New Antibiotics Russian Academy of Medical Sciences (RU)
- Nam Can Tho University (VN)
- Viện Hóa học (VN)
- Vietnam Academy of Science and Technology (VN)
Publication Details
- Journal
- Molecules
- Published
- 2026-11-12
- DOI
- https://doi.org/10.3390/molecules31224071
- Primary Topic
- Estrogen and related hormone effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Russian Science Foundation